180 related articles for article (PubMed ID: 33567764)
1. A Novel Artificially Humanized Anti-Cripto-1 Antibody Suppressing Cancer Cell Growth.
Ishii H; Zahra MH; Takayanagi A; Seno M
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33567764
[TBL] [Abstract][Full Text] [Related]
2. Cripto monoclonal antibodies.
Hu XF; Xing PX
Drug News Perspect; 2005 Jun; 18(5):293-303. PubMed ID: 16193101
[TBL] [Abstract][Full Text] [Related]
3. Antibody blockade of the Cripto CFC domain suppresses tumor cell growth in vivo.
Adkins HB; Bianco C; Schiffer SG; Rayhorn P; Zafari M; Cheung AE; Orozco O; Olson D; De Luca A; Chen LL; Miatkowski K; Benjamin C; Normanno N; Williams KP; Jarpe M; LePage D; Salomon D; Sanicola M
J Clin Invest; 2003 Aug; 112(4):575-87. PubMed ID: 12925698
[TBL] [Abstract][Full Text] [Related]
4. An evaluation of different Cripto-1 antibodies and their variable results.
Gudbergsson JM; Duroux M
J Cell Biochem; 2020 Jan; 121(1):545-556. PubMed ID: 31310365
[TBL] [Abstract][Full Text] [Related]
5. Development of conformational antibodies targeting Cripto-1 with neutralizing effects in vitro.
Focà G; Iaccarino E; Focà A; Sanguigno L; Untiveros G; Cuevas-Nunez M; Strizzi L; Leonardi A; Ruvo M; Sandomenico A
Biochimie; 2019 Mar; 158():246-256. PubMed ID: 30703478
[TBL] [Abstract][Full Text] [Related]
6. Synergistic growth inhibition and induction of apoptosis by a novel mixed backbone antisense oligonucleotide targeting CRIPTO in combination with C225 anti-EGFR monoclonal antibody and 8-Cl-cAMP in human GEO colon cancer cells.
Normanno N; Tortora G; De Luca A; Pomatico G; Casamassimi A; Agrawal S; Mendelsohn J; Bianco AR; Ciardiello F
Oncol Rep; 1999; 6(5):1105-9. PubMed ID: 10425310
[TBL] [Abstract][Full Text] [Related]
7. Cripto as a target for cancer immunotherapy.
Hu XF; Xing PX
Expert Opin Ther Targets; 2005 Apr; 9(2):383-94. PubMed ID: 15934922
[TBL] [Abstract][Full Text] [Related]
8. Targeting Nodal and Cripto-1: Perspectives Inside Dual Potential Theranostic Cancer Biomarkers.
Sandomenico A; Ruvo M
Curr Med Chem; 2019; 26(11):1994-2050. PubMed ID: 30207211
[TBL] [Abstract][Full Text] [Related]
9. Transfection with a CRIPTO anti-sense plasmid suppresses endogenous CRIPTO expression and inhibits transformation in a human embryonal carcinoma cell line.
Baldassarre G; Bianco C; Tortora G; Ruggiero A; Moasser M; Dmitrovsky E; Bianco AR; Ciardiello F
Int J Cancer; 1996 May; 66(4):538-43. PubMed ID: 8635871
[TBL] [Abstract][Full Text] [Related]
10. Cripto: a novel target for antibody-based cancer immunotherapy.
Xing PX; Hu XF; Pietersz GA; Hosick HL; McKenzie IF
Cancer Res; 2004 Jun; 64(11):4018-23. PubMed ID: 15173016
[TBL] [Abstract][Full Text] [Related]
11. Targeting the embryonic gene Cripto-1 in cancer and beyond.
Bianco C; Salomon DS
Expert Opin Ther Pat; 2010 Dec; 20(12):1739-49. PubMed ID: 21073352
[TBL] [Abstract][Full Text] [Related]
12. An antibody-cytotoxic conjugate, BIIB015, is a new targeted therapy for Cripto positive tumours.
Kelly RK; Olson DL; Sun Y; Wen D; Wortham KA; Antognetti G; Cheung AE; Orozco OE; Yang L; Bailly V; Sanicola M
Eur J Cancer; 2011 Jul; 47(11):1736-46. PubMed ID: 21458984
[TBL] [Abstract][Full Text] [Related]
13. Differential immunohistochemical detection of transforming growth factor alpha, amphiregulin and CRIPTO in human normal and malignant breast tissues.
Panico L; D'Antonio A; Salvatore G; Mezza E; Tortora G; De Laurentiis M; De Placido S; Giordano T; Merino M; Salomon DS; Mullick WJ; Pettinato G; Schnitt SJ; Bianco AR; Ciardiello F
Int J Cancer; 1996 Jan; 65(1):51-6. PubMed ID: 8543395
[TBL] [Abstract][Full Text] [Related]
14. Recombinant humanized Fab fragments targeting the CFC domain of human Cripto-1.
Sandomenico A; Selis F; Sivaccumar JP; Olimpieri P; Iaccarino E; Cicatiello V; Cantile M; Sanna R; Leonardi A; De Falco S; Ruvo M
Biochem Biophys Res Commun; 2024 Jan; 694():149417. PubMed ID: 38150919
[TBL] [Abstract][Full Text] [Related]
15. Exogenous Cripto-1 Suppresses Self-Renewal of Cancer Stem Cell Model.
Alam MJ; Takahashi R; Afify SM; Oo AKK; Kumon K; Nawara HM; Khayrani AC; Du J; Zahra MH; Seno A; Salomon DS; Seno M
Int J Mol Sci; 2018 Oct; 19(11):. PubMed ID: 30373174
[TBL] [Abstract][Full Text] [Related]
16. The role of Cripto-1 in the tumorigenesis and progression of oral squamous cell carcinoma.
Yoon HJ; Hong JS; Shin WJ; Lee YJ; Hong KO; Lee JI; Hong SP; Hong SD
Oral Oncol; 2011 Nov; 47(11):1023-31. PubMed ID: 21824804
[TBL] [Abstract][Full Text] [Related]
17. Genetic variants modulating CRIPTO serum levels identified by genome-wide association study in Cilento isolates.
Ruggiero D; Nappo S; Nutile T; Sorice R; Talotta F; Giorgio E; Bellenguez C; Leutenegger AL; Liguori GL; Ciullo M
PLoS Genet; 2015 Jan; 11(1):e1004976. PubMed ID: 25629528
[TBL] [Abstract][Full Text] [Related]
18. Cripto-1 promotes resistance to drug-induced apoptosis by activating the TAK-1/NF-κB/survivin signaling pathway.
Zhang Y; Mi X; Song Z; Li Y; YingShi ; Niu J
Biomed Pharmacother; 2018 Aug; 104():729-737. PubMed ID: 29807222
[TBL] [Abstract][Full Text] [Related]
19. Cytotoxic targeting of F9 teratocarcinoma tumours with anti-ED-B fibronectin scFv antibody modified liposomes.
Marty C; Odermatt B; Schott H; Neri D; Ballmer-Hofer K; Klemenz R; Schwendener RA
Br J Cancer; 2002 Jul; 87(1):106-12. PubMed ID: 12085265
[TBL] [Abstract][Full Text] [Related]
20. Design, expression and characterization of a single chain anti-CD20 antibody; a germline humanized antibody derived from Rituximab.
Ahmadzadeh V; Farajnia S; Hosseinpour Feizi MA; Khavarinejad RA
Protein Expr Purif; 2014 Oct; 102():45-51. PubMed ID: 25088934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
